Drugs / Human COVID-19 immunoglobulin
Human COVID-19 immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05173441 | Dec 2021 → Jun 2023 | COVID-19 | Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human COVID-19 immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05173441 ↗ |
| Modality | Protein / enzyme biologic | “Human COVID-19 immunoglobulin” NCT05173441 ↗ |
| Route | Intravenous | “COVID-HIG will be administered via intravenous infusion.” NCT05173441 ↗ |